110 related articles for article (PubMed ID: 37302280)
21. BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy.
Samanta D; Huang TY; Shah R; Yang Y; Pan F; Semenza GL
Cell Rep; 2020 Aug; 32(8):108073. PubMed ID: 32846130
[TBL] [Abstract][Full Text] [Related]
22. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
23. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
24. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
26. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
27. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
[TBL] [Abstract][Full Text] [Related]
28. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccines.
Węgierek-Ciura K; Mierzejewska J; Szczygieł A; Rossowska J; Wróblewska A; Świtalska M; Goszczyński TM; Szermer-Olearnik B; Pajtasz-Piasecka E
Front Immunol; 2023; 14():1212606. PubMed ID: 37545526
[TBL] [Abstract][Full Text] [Related]
30. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
31. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
32. Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.
Ivasko SM; Anders K; Grunewald L; Launspach M; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Lode HN; Andersch L; Schulte JH; Eggert A; Hundsdoerfer P; Künkele A; Zirngibl F
Front Immunol; 2022; 13():1023206. PubMed ID: 36700232
[TBL] [Abstract][Full Text] [Related]
33. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Quezada SA; Peggs KS; Curran MA; Allison JP
J Clin Invest; 2006 Jul; 116(7):1935-45. PubMed ID: 16778987
[TBL] [Abstract][Full Text] [Related]
34. Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity.
Yang P; Song H; Qin Y; Huang P; Zhang C; Kong D; Wang W
Nano Lett; 2018 Jul; 18(7):4377-4385. PubMed ID: 29932335
[TBL] [Abstract][Full Text] [Related]
35. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
[TBL] [Abstract][Full Text] [Related]
36. Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.
Azulay M; Shahar M; Shany E; Elbaz E; Lifshits S; Törngren M; Friedmann A; Kramer R; Hedlund G
J Transl Med; 2023 Mar; 21(1):222. PubMed ID: 36967382
[TBL] [Abstract][Full Text] [Related]
37. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
38. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
[TBL] [Abstract][Full Text] [Related]
39. Alarmin augments the antitumor immunity of lentiviral vaccine in ectopic, orthotopic and autochthonous hepatocellular carcinoma mice.
Liu Z; Lu Z; Jing R; Zuo B; Gao X; Han G; Qi H; Wu L; Liu Y; Yin H
Theranostics; 2019; 9(14):4006-4018. PubMed ID: 31281528
[TBL] [Abstract][Full Text] [Related]
40. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]